Literature DB >> 10382905

Congenital myasthenic syndrome caused by a mutation in the Ets-binding site of the promoter region of the acetylcholine receptor epsilon subunit gene.

K Ohno1, B Anlar, A G Engel.   

Abstract

Forty-two missense, truncation, or splice-site mutations of the acetylcholine receptor (AChR) subunit genes have been reported to date in patients with congenital myasthenic syndromes. Here we report a homozygous mutation, epsilon-155G --> A, in the promoter region of the AChR epsilon subunit gene that converts the Ets-binding site of the promoter region from CGGAA to CAGAA. The asymptomatic parents and brother are heterozygous and an affected sister is homozygous for epislon-155G --> A. The Ets-binding site mediates synapse specific expression of the AChR epsilon subunit gene. An identical G-to-A mutation in the mouse Ets-binding site was previously shown to decrease the binding affinity of the Ets-binding site for the GA binding protein, a transactivating factor for the Ets-binding site, and to reduce the synapse specific expression of the epsilon subunit. The decreased synaptic expression of the epsilon subunit readily accounts for the congenital myasthenic phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382905     DOI: 10.1016/s0960-8966(99)00007-3

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  16 in total

1.  The Ets transcription factor GABP is required for postsynaptic differentiation in vivo.

Authors:  A Briguet; M A Ruegg
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Targeting of the ETS factor GABPalpha disrupts neuromuscular junction synaptic function.

Authors:  Debra A O'Leary; Peter G Noakes; Nick A Lavidis; Ismail Kola; Paul J Hertzog; Sika Ristevski
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

3.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

Review 4.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

Review 5.  Extracellular signal-regulated kinases 1 and 2 regulate neuromuscular junction and myofiber phenotypes in mammalian skeletal muscle.

Authors:  Mendell Rimer
Journal:  Neurosci Lett       Date:  2019-12-02       Impact factor: 3.046

6.  A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction.

Authors:  Mohsen Afshar Bakooshli; Ethan S Lippmann; Ben Mulcahy; Nisha Iyer; Christine T Nguyen; Kayee Tung; Bryan A Stewart; Hubrecht van den Dorpel; Tobias Fuehrmann; Molly Shoichet; Anne Bigot; Elena Pegoraro; Henry Ahn; Howard Ginsberg; Mei Zhen; Randolph Scott Ashton; Penney M Gilbert
Journal:  Elife       Date:  2019-05-14       Impact factor: 8.140

7.  GA-binding protein is dispensable for neuromuscular synapse formation and synapse-specific gene expression.

Authors:  Alexander Jaworski; Cynthia L Smith; Steven J Burden
Journal:  Mol Cell Biol       Date:  2007-05-07       Impact factor: 4.272

8.  Regulation of the rapsyn promoter by kaiso and delta-catenin.

Authors:  Marianna Rodova; Kevin F Kelly; Michael VanSaun; Juliet M Daniel; Michael J Werle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

9.  Expression of mutant Ets protein at the neuromuscular synapse causes alterations in morphology and gene expression.

Authors:  Alban de Kerchove D'Exaerde; Jean Cartaud; Aymeric Ravel-Chapuis; Thierry Seroz; Fabien Pasteau; Lindsay M Angus; Bernard J Jasmin; Jean-Pierre Changeux; Laurent Schaeffer
Journal:  EMBO Rep       Date:  2002-10-22       Impact factor: 8.807

10.  Phosphorylation-elicited quaternary changes of GA binding protein in transcriptional activation.

Authors:  Morten Sunesen; Monique Huchet-Dymanus; Morten O Christensen; Jean-Pierre Changeux
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.